




Medlab AGM Investor Presentation

Friday 10 November 2017, *Hall Chadwick*


By reading this document, the Recipient acknowledges that the information contained is confidential and has been prepared only to provide information about the investment to the Recipient and its advisers and for no other purpose.

Medlab's unique process for CBD/THC Cannabis

Processed
Cannabis



NanoCelled Cannabis
(CBD+THC)
ready for packing



Doctors label for NanaBis™
NanoCelle Cannabis
(CBD+THC) ready for use



Executive Summary

- NanaBis™ (cannabis CBD/THC) for advanced cancer pain. Clinical trial approved. Currently in manufacture at PPP Melbourne.*
- NanaBidal™ (cannabis CBD) for chemotherapy induced nausea and vomiting as well as seizures. Clinical trial approved.*

*** TGA licence renewed for import of substantially increased quantities of CBD and THC cannabis.**

Executive Summary - *cont'd.*


- NanoStat™ Atorvastatin bioequivalence pilot, potential for lower dose and lower side effects of statins (Lipitor®). Patent pending.
- NRGBiotic™ for the management of treatment resistant depression patients prescribed an SSRI (selective serotonin re-uptake inhibitor). PATENTED. Two successful phase 1 clinical trials completed, clinical trial Phase 2A approved.
- Nutraceutical Business - total revenue FY17 up 70% (Q1 18 collections increase of 67%). Marketing agreement with Heritage Brands launch expected early 2018.
- Senior Management Team and Board bullish on outlook for next 18 months to 2 years.



Business Model




5 key research areas in chronic diseases



- Short timelines, Phase 2a conclusion being exit point
- Nutraceutical sales provide revenue source

Research Progression


NanaBis™
(CBD & THC) cannabis
PATENT PENDING



NanaBidal™
(CBD) cannabis
PATENT PENDING




NanoStat™
(Atovorastatin)
PATENT PENDING



NRGBiotic™
(Depression)
PATENTED



T2Biotic™
(Diabetes)
PATENT PENDING



 = indicates current progression

Looking forward

PILLAR 1: COMMITMENT TO RESEARCH



PILLAR 2: NUTRACEUTICAL GROWTH



PILLAR 3: COMMERCIALISATION



RESEARCH, COMMERCIALISATION AND GROWTH

1. Bringing NanaBis™ (NanoCelle™ Cannabis THC+CBD) to the AU market. (130,000 new Australian patients diagnosed with advanced cancer pain every year).
2. Bringing NanaBidal™ (NanoCelle™ Cannabis CBD only) to the AU and US markets. (US 1.7M new patients undergo chemotherapy every year of which 1/3 suffer chemotherapy induced nausea and vomiting).
3. Bringing NanoStat™ (NanoCelle™ Atorvastatin) to the AU market. (73.5 million adults in the US and AU).
4. Complete depression phase 2A trials, NRGBiotic™ as adjuvant therapy for SSRI resistant patients (Depression as per World Health Organisation 5% world population).

Looking forward - *cont'd.*

PILLAR 1: COMMITMENT TO RESEARCH



PILLAR 2: NUTRACEUTICAL GROWTH



PILLAR 3: COMMERCIALISATION




RESEARCH, COMMERCIALISATION AND GROWTH

5. Complete Diabetic and Pre Diabetic Phase 2A trials, T2Biotic as an adjuvant therapy for pre diabetic and type 2 diabetic patients (US stats 27 million type 2 diabetic patients and growing, 86 million pre diabetic patients and growing).
6. Growth in both domestic and export of nutraceutical and pharmaceutical business (current Australian complimentary medicine market projected to be in excess of \$4.7 Billion). Over the next two years subject to no unforeseen circumstances your Board and Senior Management expect our sales to increase significantly based on natural growth from current products plus obvious sales expansion from the products derived from our research as outlined above.

Nutraceuticals


- Our Nutraceutical range has continued to grow since our listing in July 2015. We currently have 10 of our products under patent, with applications lodged for further patents.
- Our range is practitioner recommended and endorsed.



Presentation for information purposes only. All rights reserved. For more information please contact Sean Hall +61 411603378, or sean_hall@medlab.co

Patents

STRONG IP PORTFOLIO



Thank You

Sean Hall MD, MBA (Clin Phm Mgt)
Medlab Clinical Limited
ASX: MDC
Phone: +61 2 8188 0311
Email: sean_hall@medlab.co

www.medlab.co
<https://au.linkedin.com/in/seanhallbio>
www.facebook.com/MedlabAUS

